New drug aims to tame rare artery disease
NCT ID NCT07477795
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether secukinumab, a drug that blocks IL-17A, can help people with active severe Takayasu arteritis achieve remission and stop taking steroids. About 52 participants will receive either secukinumab injections or standard care (like TNF inhibitors). The main goal is to see if more patients reach remission at 6 months without steroids.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Secukinumab (a drug that blocks IL-17A, given as injections under the skin)
- What this could lead to
- If it works, this could offer a new treatment option for severe Takayasu arteritis, helping patients achieve remission and reduce reliance on steroids.
- What could go wrong
- This is a small, early-phase (Phase 2) study with only 52 participants. Previous similar drugs have failed in larger trials, and the drug may not work or could have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LARGE VESSEL VASCULITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Immune clues in the blood may foretell heart trouble
- Rare artery disease linked to higher heart attack and stroke risk
- New Total-Body PET scanner could revolutionize vasculitis diagnosis
- 5,000 patients to help unlock secrets of inflammatory heart disease
- Super-Sharp brain scanner could revolutionize diagnosis of dementia and cancer
- New study links common arthritis treatments to diabetes risk